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Abstract
Structural optimizations of the prior lead 1a led to the discovery of a series of N-aryl-6-
methoxy-1,2,3,4-tetrahydroquinoline derivatives as a novel class of tubulin polymerization
inhibitors targeted at the colchicine binding site. The most active compound 6d showed extremely
high cytotoxicity against a human tumor cell line panel (A549, KB, KBvin, and DU145) with GI50
values ranging from 1.5 to 1.7 nM, significantly more potent than paclitaxel, especially against the
drug-resistant KBvin cell line, in the same assays. Analogues 5f, 6b, 6c, and 6e were also quite
potent, with a GI50 range of 0.011–0.19 μM. In further studies, active compounds 6b–6e and 5f
significantly inhibited tubulin assembly, with IC50 values of 0.92 to 1.0 μM and strongly inhibited
colchicine binding to tubulin, with inhibition rates of 75–99% (at 5 μM), comparable with or more
potent than combretastatin A-4 (IC50 0.96 μM). Current studies included design, synthesis, and
biological evaluations of 24 new compounds (series 3–6). Related SAR analysis, molecular
modeling, and evaluation of essential drug-like properties, i.e. water solubility, log P, and in vitro
metabolic stability, were also performed.
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Microtubules, formed by a dynamic polymerization and depolymerization of α- and β-
tubulin heterodimers, play important roles in cellular activities [1]. For many years, certain
drugs that bind to the taxol or vinca site on tubulin, such as paclitaxel and vinblastine, have
been widely used in the clinic to treat cancers [2]. However, their narrow therapeutic
windows and the emergence of drug resistance have encouraged continued efforts to
discover safer and more effective agents capable of treating resistant cancer phenotypes.
Another natural product colchicine (Figure 1) binds to a unique site on tubulin, distinct from
the above two binding sites, and_can effectively inhibit tubulin assembly. Even though
colchicine is not used clinically because of its high toxicity, other small molecules bind at
the colchicine site, e.g., N-deacetyl-N-(2-mercaptoacetyl)-colchicine (DAMA-colchicine)
and combretastatin A-4 (CA-4), and some have exhibited high potency, lower toxicity, and
greater efficacy against cancers resistant to existing tubulin-targeting drugs [3]. More
attractively, some of these compounds exhibit a vascular disrupting effect on vascular
endothelial cells and have entered into clinical development as vascular disrupting agents
(VDAs) for cancer treatment. Examples of this novel class of anticancer agents are CA-4P
and ZD6126 (Figure 1) [4,5].
In our prior studies on new anticancer agents [6,7], we discovered methyl 6-chloro-2-(N-(4-
methoxyphenyl)-N-methyl)aminonicotinate (1a, Figure 2) as a lead compound with potent
cytotoxic activity (GI50 0.20–0.26 μM) against A549, KB, KBvin, and DU145 human tumor
cell lines. Its biological target was identified as tubulin, specifically the colchicine site.
Previous related SAR studies indicated that a para-methoxyphenyl moiety (B-ring) is an
essential pharmacophore, that a tertiary amine linker can provide a feasible binding
conformation, and that the substituted pyridine ring (A-ring) can be modified to improve
potency. Based on these known SAR findings, we pursued optimization of lead 1a,
following the strategies shown in Figure 2, to identify additional tubulin inhibitors with new
scaffolds and high potency. Because the o-chloropyridine moiety could potentially lead to
metabolic toxicity resulting from in vivo nucleophilic replacement [8], we initially replaced
the pyridine ring (A-ring) of 1a with a benzene ring and also changed the identities and
positions of substituents R1 and X on the A-ring (series 3-4 compounds) to investigate how
these modifications impacted inhibitory activity against tumor cell growth. Previously, we
also postulated that the degree of torsional angle between the two aryl rings (A- and B-rings)
might be crucial for activity; therefore, our next modification focused on the N-linkage. By
applying a conformation restriction strategy [9], we connected a propyl group on the N-
linker to the neighboring benzene ring (B-ring) to form a six-membered fused
tetrahydropyridine ring (series 5 compounds). By constraining the flexible conformation, we
could better explore feasible binding conformations and possible ligand-target interactions.
We next postulated that introducing a fused aromatic ring onto the A-ring might make the
molecular binding conformation of new series 6 compounds more similar to that of
colchicine and enhance affinity with the binding site on tubulin, leading to better antitumor
activity. All newly synthesized compounds were evaluated by cellular screening against a
human tumor cell line (HTCL) panel, and selected potent compounds were also assayed for
tubulin inhibition. Molecular modeling was used to illustrate the interaction between tubulin
and the new ligand(s) as well as differences among ligands. Furthermore, certain essential
parameters related to drug-like properties, such as water solubility, log P, and metabolic
stability, were determined for highly potent compounds. Chemical synthesis, biological
evaluation, molecular modeling, and SAR analysis are presented in this paper.
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The syntheses of target compounds 3–6 are outlined in Schemes 1 and 2. Intermediate 2a
was prepared by Ullmann condensation reaction [10] of commercially available 4-
methoxyaniline and 2,4-dichlorobenzoic acid in the presence of Cu/Cu2O in 2-
ethoxyethanol, following esterification with DMF-DMA (two equivalents) in toluene at
reflux for 24 h. Intermediates 2b-d were obtained by a Buchwald-Hartwig coupling reaction
between 4-methoxyaniline and methyl 5-substituted-3-bromo (or iodo) benzoate in the
presence of catalyst Pd(OAc)2 and Cs2CO3 either with X-phos [11] under microwave (mw)
irradiation at 120–150 °C (Method A for 2b and 2c) or with BINAP and traditional heating
in toluene at reflux under nitrogen protection (Method B for 2d). Subsequently, secondary
amines 2a-d were treated with methyl iodide in the presence of sodium hydride to afford
corresponding tertiary diarylamines 3a and 4a-c. When using LiAlH4 in THF at 0 °C for 1 h,
the ester group of 3a was reduced to a hydroxymethyl moiety, affording 3b in nearly
quantitative yield. Compound 3b was further methylated with methyl iodide to give ether 3c.
Alternatively, the ester group in 3a and 4a-c was converted to an N-methylcarbamoyl group
by treatment with methylamine in MeOH under mw irradiation at 100–120 °C to produce
corresponding compounds 3d and 4d-f, respectively, in high yields (79–89%). Methylation
of 4f with methyl iodide yielded compound 4g with a N,N-dimethylcarbamoyl group on the
A-ring. Ester compound 4c was hydrolyzed under basic conditions to produce carboxylic
acid compound 4h. Compound 4h was then treated with 1-hydroxybenzotriazole (HOBt) in
the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) hydrochloride salt,
followed by reaction with cyclopropylamine or cyclopentylamine to produce corresponding
N-cyclopropylamide and N-cyclopentylamide compounds 4i and 4j, respectively [12]. By
using Buchwald-Hartwig coupling reactions and the same conditions, compounds 5a-5b and
6a-6b were synthesized from intermediate 6-methoxy-1,2,3,4-tetrahydroquinoline (7) [13]
and an aryl halide, such as phenyl, naphthyl, and quinolyl halides, in 68–75% yields.
Similarly to series 3 and 4, the ester group in 5a and 5b was converted into an N-alkyl
carbamoyl or carboxy group to provide corresponding compounds 5c-f by using the same
methods described above. Differently from 6a and 6b, the preparation of 6c and 6d involved
coupling 7 with a 2-substituted 4-haloquinazoline under EtOH reflux in the presence of
NaHCO3, resulting in 79–87% yields. Using the same method for preparing 5c, compound
6d was converted to 6e. All new series 3-6 compounds were identified by 1H NMR and MS
spectroscopic data, with purity determined by HPLC.
3. Results and Discussion
3.1 Evaluation of Cytotoxicity and Tubulin Inhibition Activity in Vitro
The 24 newly synthesized tertiary arylamines (series 3–6) were evaluated in cellular
cytotoxicity assays against a HTCL panel, including A549 (lung carcinoma), KB
(epidermoid carcinoma of the mouth), KBvin, a P-gp-expressing multidrug-resistant cell line
(vincristine-resistant KB)[14, 15], and DU145 (prostate cancer) with paclitaxel as a
reference compound. The in vitro anticancer activity (GI50) was determined using the
established sulforhodamine B (SRB) method [16]. The cytotoxicity data of all new
compounds in HTCL assays are listed in Tables 1 and 2. Subsequently, selected compounds
with high potency in cellular assays were further tested in tubulin assays to determine
biological target and binding site.
In series 3 compounds with a phenyl A-ring and substituent X equal to m-chloro, two
compounds 3a (R1 = o-COOMe) and 3c (R1 = o-CH2OMe) showed promising potency with
low micromolar GI50 values of 1.68 to 5.24 μM, indicating that replacement of the pyridine
A-ring in lead 1a is tolerated and R1 on the A-ring is modifiable. When the COOMe group
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(R1) was moved to the meta-position on the A-ring, the resulting compound 4a exhibited
somewhat improved activity (GI50 1.46–1.61 μM) compared with 3a (R1 = o-COOMe, GI50
1.68–3.36 μM). This finding prompted us to synthesize compounds 4b-f, in which the meta-
R1 was either maintained as an ester (COOMe) or changed to a N-methylcarbamoyl
(CONHMe) group, while substituent X was present as either a chloro, trifluoromethyl or
bromo group. Interestingly, compounds 4a, 4c, 4d, and 4f where X is either chloride or
bromide were more potent than 3a. In addition, compounds 4d and 4f with a meta-N-
methylcarbamoyl group (R1) showed significantly improved potency with a GI50 range of
0.14–0.30 μM, compared with related meta-ester compounds 4a and 4c. In contrast, 4b and
4e with a trifluoromethyl (X) group were less active than corresponding chloro- and bromo-
compounds in the same assays, Next, the cytotoxicity results for bromo-substituted
compounds 4g-j revealed the impact of the m-alkanoyl group (R1). When the meta-N-
methylcarbamoyl (4f) or meta-ester (4c) was converted to a more bulky N,N-
dimethylcarbamoyl (4g) or more polar carboxy (4f) group, potency decreased or was
abolished completely, respectively. But when R1 was an N-cyclopropylcarbamoyl or N-
cyclopentylcarbamoyl group, the corresponding compounds 4i and 4j showed improved
potency with GI50 values of 0.11 to 0.17 μM, more potent than the other series 3 and 4
compounds, as well as 1a. Because corresponding series 4 compounds (4a, 4d) were more
potent than series 3 compounds (3a, 3d), we postulated that the meta-substitution on the A-
ring might favor an appropriate torsional angle between the two aromatic rings, due to
decreased steric hindrance around the N-linker, which would be consistent with our prior
hypothesis. Moreover, the high potency of 4d, 4f, 4i, and 4j demonstrated that a
hydrophobic meta-N-alkylcarbamoyl group with a suitable volume could enhance antitumor
potency.
When the N-linker between the A- and B-rings was incorporated into a six-membered
1,2,3,4-tetrahydropyridine ring fused with the B-ring, all five compounds 5a-d,f exhibited
high cytotoxicity with GI50 values of 0.15 to 2.33 μM (Table 1). Thus, the ring-restricted N-
linker was favorable for cytotoxic activity. Consequently, all series 6 compounds contain a
6-methoxy-1,2,3,4-tetrahydroquinoline moiety connected to an aromatic (naphthalene) or
heteroaromatic (quinoline or quinazoline) bicyclic ring system, in which the resonance
system of the A-ring is extended over an additional fused aromatic ring. As shown in Table
2, except for 6a with a naphthyl A-ring system, compounds with either a quinoline (6b) or
quinazoline (6c-6e) moiety exhibited extremely high cytotoxicity in the HTCL assays.
Among them, 6d with a 2-chloroquinazoline moiety (A-ring) was the most potent with GI50
values ranging from 1.5 to 1.7 nM. Thus, 6d was more potent than paclitaxel in the same
assays, especially against the drug-resistant KBvin cell line (GI50 0.0017 μM versus 1.21
μM, respectively). Compounds 6b (2-methylquinoline), 6c (2-methylquinazoline), and 6e
(2-methylaminoquinazoline) also showed high cytotoxicity with a GI50 range of 11-91 nM,
more potent by at least ten-fold than 1a and series 3-5 compounds. Similarly to 6d, analogs
6b, 6c, and 6e were also much more potent than paclitaxel against KBvin cell growth,
indicating that this compound type has great potential to overcome resistance to paclitaxel.
Based on these results in cellular assays, active compounds 4f, 4i, 5f, and 6b-e (GI50 < 1
μM) were evaluated in tubulin inhibition assays, in parallel with CA-4, a drug candidate in
clinical trials, as a reference. As shown in Table 3, while N-methyl linked compounds 4f and
4i (open N-linker) showed good inhibitory potency against tubulin assembly (IC50 1.6–2.2
μM), the N-phenyl-6-methoxy-1,2,3,4-tetrahydroquinoline compound 5f (ring-restricted N-
linker) exhibited improved potency in both tubulin assembly (IC50 1.0 μM) and colchicine
binding (75%) assays. Thus, the presence of the ring-restricted N-linker probably increases
compound affinity for tubulin. Furthermore, 6b-e with both a ring-restricted N-linker and a
fused bicyclic aromatic ring system (A-ring) also displayed high potency in the tubulin
Wang et al. Page 4













assembly (IC50 0.92–1.00 μM) and inhibition of colchicine binding (87–99% at 5 μM and
61–95% at 1 μM) assays, comparable with and greater than those of 5f, respectively.
Consistent with the cellular assays, compound 6d was the most potent compound with an
IC50 value of 0.93 μM against tubulin assembly and inhibitory rates of 99% and 95% at 5
μM and 1 μM, respectively, for competitively inhibiting colchicine binding to tubulin. These
data are comparable or better than those for the reference compound CA-4 (IC50 0.96 μM,
98% and 90% respectively). Thus, N-aryl-6-methoxy-1,2,3,4-tetrahydroquinoline
compounds, e.g., series 5-6, likely present a novel class of highly potent tubulin
polymerization inhibitors targeted at the colchicine binding site. Meanwhile, we postulated
that a fused bicyclic aromatic A-ring might interact with the colchicine site in some way,
possibly resulting in increased affinity for tubulin. On the other hand, the active 6 series
compounds might also interact with other unidentified target(s), because 6b-e displayed
much higher potency than 5f in the cellular cytotoxicity assays, but similar inhibitory
activity against tubulin polymerization.
3.2 Molecular Modeling
To better understand interactions between the newly synthesized active inhibitors and
tubulin, we investigated potential binding modes of active compounds 4i, 5f, and 6d at the
colchicine site in the tubulin dimer by using the CDOCKER program in the Discovery
Studio 3.0 software with the tubulin crystal structure (PDB: 1SA0) [17,18], as in our
previous study. In the binding models shown in Figure 3A, both 4i (purple) and 5f (green)
displayed low energy binding conformations (-30.58 and -33.31 kcal/mol, respectively) that
superimposed well with each other and with DAMA-colchicine (cyan), the ligand used in
the tubulin crystal structure. As seen in Figure 3A, a hydrogen bond is present between
Val181 in the α-T5 loop of tubulin and the amide carbonyl group on the A ring of 4i and 5f.
This hydrogen bond is also observed between Val181 and the carbonyl group on the C-ring
of DAMA-colchicine. In addition, the N-cyclopropyl of the amide group in both 4i and 5f
overlaps with the methoxy group on the seven-membered ring (C-ring) of DAMA-
colchicine and stretches into a small lipophilic pocket around the amino acids in α-T5, β-H8,
β-S8 and β-S9 of tubulin. In addition, the 4-methoxyphenyl moiety (B-ring) in 4i and 5f,
regardless of whether the N-linker is open or ring-restricted, overlaps with the
trimethoxyphenyl portion of DAMA-colchicine. The 4-OCH3 group on the B-ring of 4i and
5f forms a hydrogen bond with the Cys241 side chain in β-H7 of tubulin, and a similar
interaction is also observed with the 2′-OCH3 on the A-ring of DAMA-colchicine. Cys241 is
a key amino acid that interacts with most tubulin inhibitors bound at the colchicine site. In
the crystal structure, the C5 and C6 atoms of the B-ring of DAMA-colchicine are involved
in hydrophobic interactions with the side chains of Alaβ250 and Leuβ255 in tubulin's β-H8
region. Although the N-CH3 linker in 4i is not in close proximity to Alaβ250 and Leuβ255
(> 4Å), the added carbons in the six-membered tetrahydropyridine cyclic linker in 5f are
closer to the hydrophobic side chains of Alaβ250 and Leuβ255 (< 4Å). The additional van
der Waal's force between the cyclic linker and the binding site would likely strengthen
affinity of 5f for tubulin. Therefore, our current modeling results might explain, at least
partially, the higher potency of 5f than 4f and 4i in the tubulin assays (Table 3).
Consistent with our earlier hypothesis [6,7], the steric hindrance of the N-CH3 linker [19]
results in a binding torsional angle of 74.89 ° between the two aromatic rings in 4i, allowing
the N-alkyl amide group on the A-ring to interact with the binding site as described above.
When the N-linker is connected with additional carbons into a six-membered ring, a similar
torsional angle (70.52 °) was found, maintaining a favorable binding conformation for 5f
and all major interactions with the binding site as mentioned above for 4i. Figure 3B shows
that 6d (binding energy: -34.39 kcal/mol) has a similar binding orientation as those of 4i and
5f, as well as good superimposition with DAMA-colchicine. The major interactions of the
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B-ring and the cyclic linker with tubulin are maintained. The torsional angle (69.07°)
between the two rings in 6d is similar to that of 5f, resulting in a superimposition between
the quinazoline ring of 6d and the aromatic C-ring of DAMA-colchicine. Although we
postulated that the fused aromatic ring introduced in 6d would play a role similar to that of
the C-ring of colchicine within the binding site on tubulin, no interaction was obvious in the
computational model. Because of the torsional angle between the two aryl rings, the 2-
chloro group on the quinazoline in 6d [as well as the m-bromo group on the phenyl (A-ring)
in 4i and 5f (Figure 3A)] was orientated similarly to the acetyl group on the B-ring in
DAMA-colchicine. Thus, the X substituent on the quinazoline (or other aromatic ring
system) might interact with tubulin in some way and be modifiable.
3.3 Drug-like property evaluations
Next, we evaluated aqueous solubility and logP parameters of 4f, 4i, 5f, 6b, 6c, 6d and 6e as
described previously [20]. As shown in Table 4, compounds 6b, 6c, and 6e showed much
better aqueous solubility (3.21–7.67 μg/mL) than the other four compounds (□ 1.0 μg/mL).
Consistently, log P values of 6b, 6c, and 6e (1.07–3.98) were also lower (4f, 4i, 5f, 6d >4).
Subsequently, metabolic stability of 6b-6e was further evaluated by an in vitro human liver
microsome incubation assay with propranolol (moderate metabolism in vivo, t1/2 3–5 h) and
terfenadine (fast metabolism in vivo, t1/2 < 3 h) as positive controls. Compounds 6c (t1/2
25.19 min) and 6e (t1/2 25.97 min) were more stable than terfenadine (t1/2 21.14), while 6b
and 6d were even less stable with short metabolic half-lives of 7.89 min and 10.59 min,
respectively, indicating quick metabolism. In general, a potent compound with low
metabolic stability is not usually recognized as a promising drug candidate. However,
compounds targeting the colchicine site of tubulin are proposed as VDAs to treat cancers.
For this new type of anticancer drug candidate, rapid metabolism might be desirable to
decrease drug toxicity in the body, as exemplified by ZD6126 (Fig. 1), which was developed
based on this hypothesis [21].
4. Conclusion
Modifications of prior lead 1a resulted in the synthesis and biological evaluation of 24 new
compounds (series 3-6). During this process, active compound 6d showed extremely high
cytotoxicity against the screening HTCL panel with a GI50 value range of 1.5–1.7 nM, more
potent than paclitaxel in the same assays, especially against resistant KBvin. Compound 6d
also displayed significant inhibitory activity in tubulin assembly (IC50 0.93 μM) and
colchicine binding (inhibition 99% at 5 μM and 95% at 1 μM) assays, with greater potency
than CA-4. Similarly, analogues 6b, 6c, and 6e also showed high potency in the cellular
(GI50 11–91 nM) and tubulin (IC50 0.92–1.0 μM) assays. Therefore, N-aryl-6-
methoxy-1,2,3,4-tetrahydroquinoline derivatives were identified as a novel class of tubulin
polymerization inhibitors targeted at the colchicine site. Current SAR studies lead to the
following conclusions: (1) a ring-restricted N-linker is beneficial and provides a feasible
torsional angle (about 70-75°) between the two aryl ring systems (A and B rings) for
enhancing molecular affinity for tubulin; (2) the 6-methoxy-1,2,3,4-tetrahydroquinoline
moiety can serve as a pharmacophore and the methoxy group on the B-ring is a necessary
binding point to tubulin; (3) isosteric replacement of the A-ring is feasible and a fused
aromatic ring, such as quinoline and quinazoline, improved molecular potency; (4) various
m-substituents on the A-ring are present in active compounds, and either halogen or N-alkyl
amide/amino might be beneficial. Molecular modeling results illustrated some possible
interactions of the active compounds with the colchicine site of tubulin and supported our
earlier hypothesis that a feasible torsional angle between the two aryl rings might be
important for high potency. An evaluation of essential drug-like properties, i.e. water
solubility, log P, and metabolic stability in vitro, also provided useful information. These
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results will help us to develop drug candidates from this novel class of tubulin inhibitors
targeted at the colchicine site in further studies.
5. Experimental Section
5.1. Chemistry
Proton and carbon nuclear magnetic resonance (1H and 13C NMR) spectra were measured
on a JNM-ECA-400 (400 MHz) spectrometer using tetramethylsilane (TMS) as internal
standard. The solvent used was CDCl3 unless otherwise indicated. Mass spectra (MS) were
measured on an API-150 mass spectrometer with an electrospray ionization source from
ABI, Inc. Melting points were measured by a SGW X-4 Micro-Melting point detector
without correction. The mw reactions were performed on a mw reactor from Biotage, Inc.
Medium- pressure column chromatography was performed using a CombiFlash®
Companion system from ISCO, Inc. Thin-layer chromatography (TLC) was performed on
silica gel GF254 plates. Silica gel GF254 and H (200–300 mesh) from Qingdao Haiyang
Chemical Company were used for TLC and column chromatography, respectively. All
commercial chemical reagents were purchased from Beijing Chemical Works or Sigma-
Aldrich, Inc. Reagents NADPH, MgCl2, KH2PO4, K2HPO4, and reference compounds
propranolol and terfenadine were purchased from Sigma-Aldrich. HPLC grade acetonitrile
for LC–MS analysis was purchased from VWR. Pooled human liver microsomes (lot no.
28831) were purchased from BD Biosciences (Woburn, MA). Purities of target compounds
were determined by using an Agilent HPLC-1200 with UV detector and an Agilent Eclipse
XDB-C18 column (150 mm × 4.6 mm, 5 μm), flow rate 0.8 mL/min, UV detection at 254
nm, and injection volume of 15 μL. Mobile elution was conducted with a mixture of
solvents A and B [Condition 1: acetonitrile (ACN)/water 60~80/40~20; Condition 2:
MeOH/water 70~90/30~10]. For 6b, 6c and 6e, solvent B contained 0.025 mM ammonium
acetate.
5.1.1. Methyl 4-chloro-2-(4-methoxyphenyl)aminobenzoate (2a)—A mixture of
2,4-dichloro-benzoic acid (1.91 g, 10 mmol), 4-methoxyaniline (1.29 g, 10.5 mmol), copper
powder (58 mg, 9% mmol), cuprous oxide (58 mg, 4% mmol), anhydrous potassium
carbonate (1.38 g, 10 mmol) and 2-ethoxyethanol (7.5 mL) was refluxed under N2
protection for 24 h with stirring. The mixture was poured into water and active carbon
added. After filtration through Celite, the filtrate was adjusted to pH 3-4 with aq HCl. The
collected gray solid was dried to obtain 1.85 g of 4-chloro-2-(4-
methoxyphenyl)aminobenzoic acid (0.83 g, 3.0 mmol), which was methylated directly with
DMF-DMA (0.79 mL, 6.0 mmol) in toluene (12 mL) under reflux for 2 h. After removal of
solvent in vacuo, the residue was purified by flash column chromatography (gradient
elution: EtOAc/petroleum ether, 0-30%) to obtain 0.74 g of 2a in a 57% yield over two
steps. It was used next without further purification.
5.1.2. Methyl 3-chloro-5-(4-methoxyphenylamino)benzoate (2b)—A mixture of
methyl 3-chloro-5-iodobenzoate (296 mg, 1.0 mmol), 4-methoxyaniline (148 mg, 1.2
mmol), Cs2CO3 (455 mg, 1.4 mmol), X-Phos (17 mg, 0.04 mmol), Pd(OAc)2 (11 mg, 0.05
mmol), Celite (228 mg), and t-BuOH (0.5 mL) in toluene (3 mL) was heated at 120 °C for 1
h under mw irradiation with stirring. EtOAc (10 mL) was added to the mixture, and, after
brief stirring, insoluble solid was removed by filtration. After removal of organic solvent in
vacuo, the residue was purified by flash column chromatography (gradient elution: EtOAc/
petroleum ether, 0-40%) to obtain 2b as a yellow solid, 216 mg, 74% yield, which was used
directly in the next step without further purification.
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5.1.3. Methyl 3-trifluoromethyl-5-(4-methoxyphenylamino)benzoate (2c)—A
mixture of methyl 3-trifluoromethyl-5-bromobenzoate (285 mg, 1.0 mmol), 4-
methoxyaniline (147 mg, 1.2 mmol), Cs2CO3 (455 mg, 1.4mmol), X-Phos (17 mg, 0.04
mmol), Pd(OAc)2 (11 mg, 0.05 mmol), Celite (228 mg), and t-BuOH (0.5 mL) in toluene
(3.0 mL) was heated at 150 °C for 30 min under mw irradiation. After work-up as for 2b,
240 mg of 2c was obtained in 74% yield, yellow solid, which was directly used for the next
step without further purification.
5.1.3. Methyl 3-bromo-5-(4-methoxyphenylamino)benzoate (2d)—A mixture of
methyl 3,5-dibromobenzoate (294 mg, 1.0 mmol), 4-methoxyaniline (146 mg, 1.2 mmol),
Cs2CO3 (455 mg, 1.4mmol), BINAP (31 mg, 0.05 mmol), and Pd(OAc)2 (11 mg, 0.05
mmol) in toluene (5- 10 mL) was refluxed for 12 h under nitrogen protection. After the
mixture was cooled to rt, EtOAc (10 mL) was added. After stirring, the insoluble material
was removed by filtration. The solvent was removed in vacuo, and the residue was purified
by flash column chromatography (gradient elution: EtOAc/petroleum ether, 0-40%) to
produce 215 mg of 2d in 64% yield as a brown oil.
5.1.4. General procedure for methylation of aniline NH with methyl iodide to
prepare 3a and 4a-c—To a solution of a diarylamine (2) and MeI (molar ratio: 1/2-3) in
anhydrous DMF (ca. 3 mL) was slowly added NaH (2-3 equiv, 60% oil suspension) at 0 °C
with stirring over about 1 h. When the reaction was completed as monitored by TLC, the
mixture was poured into ice-water and extracted with EtOAc three times. The combined
organic phase was washed with water and brine successively and dried over anhydrous
Na2SO4 overnight. After removal of solvent in vacuo, the crude product was purified by
flash column chromatography (gradient elution: EtOAc/petroleum ether, 0-50%) to give the
corresponding methylated tertiary amine compounds.
5.1.4.1. Methyl 4-chloro-2-(N-(4-methoxyphenyl)-N-methylamino)benzoate (3a):
Starting with 2a (670 mg, 2.3 mmol), methyl iodide (0.28 mL, 4.6 mmol) and NaH (184 mg,
4.6 mmol) to produce 662 mg of 3a in 82% yield, yellow solid, mp 52-53 °C; 1H NMR δ
ppm 3.27 (3H, s, NCH3), 3.51 (3H, s, OCH3), 3.76 (3H, s, OCH3), 6.80 (4H, m, ArH-2′,3′,
5′,6′), 7.02 (1H, dd, J = 8.4 and 2.0 Hz, ArH-5), 7.15 (1H, d, J = 2.0 Hz, ArH-3), 7.55 (1H,
d, J = 8.0, ArH-6); MS m/z (%) 306 (M + 1, 100), 308 (M + 3, 26); HPLC purity 98.3%.
5.1.4.2. Methyl 3-chloro-5-(N- (4-methoxyphenyl)-N-methylamino)benzoate (4a):
Starting with 2b (322 mg, 1.10 mmol), methyl iodide (0.14 mL, 2.2 mmol) and NaH (88 mg,
2.2 mmol) to produce 328 mg of 4a in 98% yield, yellow solid, mp 58~60 °C; 1H NMR δ
ppm 3.27 (3H, s, NCH3), 3.84 (3H, s, OCH3), 3.87 (3H, s, OCH3), 7.04 (1H, t, J = 2.0 Hz,
ArH-2), 6.94 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.10 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.26 (1H,
m, ArH-4), 7.35 (1H, t, J = 2.0 Hz, ArH-6). MS m/z (%) 306 (M + 1,39), 308 (M + 3, 13),
291 (100); HPLC purity 99.3%.
5.1.4.3. Methyl 3-trifluoromethyl-5-(N-(4-methoxyphenyl)-N-methylamino)benzoate
(4b): Starting with 2c (188 mg, 0.58 mmol), methyl iodide (0.07 mL, 1.2 mmol), and NaH
(48 mg, 1.2 mmol) to produce 176 mg of 4c in 89% yield, yellow oil; 1H NMR δ ppm 3.32
(3H, s, NCH3), 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 6.95 (2H, d, J = 8.8 Hz, ArH-2′,6′),
7.04 (1H, s, ArH-2), 7.12 (2H, d, J = 8.8 Hz, ArH-3′,5′), 7.51 (1H, s, ArH-4), 7.61 (1H, s,
ArH-6). MS m/z (%) 340 (M + 1, 55), 325 (M − 14, 100); HPLC purity 98.7%.
5.1.4.4. Methyl 3-bromo-(N-(4-methoxyphenyl)-N-methylamino)benzoate (4c): Starting
with 2d (128 mg, 0.38 mmol), methyl iodide (0.07 mL, 1.1 mmol) and sodium hydride (44
mg, 1.1 mmol) to produce 115 mg of 4c in 90% yield, yellow oil; 1H NMR δ ppm 3.27 (3H,
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s, NCH3), 3.84 (3H, s, OCH3), 3.87 (3H, s, OCH3), 6.94 (3H, m, ArH-2,2′,6′), 7.10 (2H, d, J
= 8.8 Hz, ArH-3′,5′), 7.29 (1H, m, ArH-4), 7.50 (1H, s, ArH-6). MS m/z (%) 350 (M + 1,
34), 352 (M + 3, 29), 337 (M − 14, 100); HPLC purity 95.0%.
5.1.5. 5-Chloro-2-hydroxymethyl-N-(4-methoxy)phenyl-N-methylaniline (3b)—A
solution of 3a (427 mg, 1.40 mmol) in THF (4 mL) was added dropwise to LiAlH4 (108 mg,
2.89 mmol, excess) in anhydrous THF (5 mL) at 0 °C with stirring, which was continued at
the same temperature for another 1 h. After the reaction was complete, as monitored by
TLC, to the mixture was added 0.11 mL of water, 0.33 mL of 15% aq NaOH, and 0.33 mL
of water, successively, with stirring for another 10 min at rt. Then the mixture was filtered
through Celite, solvent was removed in vacuo, and the residue was purified by flash column
chromatography (gradient elution: EtOAc/petroleum ether 0-40%) to produce 377 mg of 3b
in 97% yield, brown oil; 1H NMR δ ppm 3.19 (3H, s, NCH3), 3.76 (3H, s, OCH3), 4.48 (2H,
s, OCH2), 6.68 (2H, d, J = 9.2 Hz, ArH-2′,6′), 6.79 (2H, d, J = 9.2 Hz, ArH-3′,5′), 7.12 (1H,
d, J = 2.0 Hz, ArH-3), 7.19 (1H, dd, J = 8.0 & 2.0Hz, ArH-5), 7.38 (1H, d, J = 8.0, ArH-6).
MS m/z (%) 278 (M + 1, 100), 280 (M + 3, 36).
5.1.6. 5-Chloro-2-(methoxymethyl)-N-(4-methoxy)phenyl-N-methylaniline (3c)
—Prepared in the same manner as for 3a, starting with 3b (227 mg, 0.82 mmol), methyl
iodide (0.10 mL, 1.6 mmol), and NaH (66 mg, 1.6 mmol) to produce 228 mg of 3c in 95%
yield, yellow oil; 1H NMR δ ppm 3.17 (3H, s, NCH3), 3.32 (3H, s, OCH3), 3.76 (3H, s,
OCH3), 4.26 (2H, s, OCH2), 6.60 (2H, d, J = 9.2 Hz, ArH-2′,6′), 6.79 (2H, d, J = 9.2 Hz,
ArH-3′,5′), 7.11 (1H, d, J = 2.0 Hz, ArH-3), 7.20 (1H, dd, J = 8.4 & 2.0Hz, ArH-5), 7.45
(1H, d, J = 8.4, ArH-6). MS m/z (%) 292 (M + 1, 22), 294 (M+ 3, 7), 228 (M-63, 100).
5.1.7. General procedure for preparing N-methylamides 3d, 4d-f from esters
under mw irradiation—A solution of ester compound (0.17 mmol ~ 0.40 mmol) in 3 mL
30% methylamine in MeOH was heated to 100-120 °C under mw irradiation for 1-2 h. Then
the mixture was poured into ice-water, neutralized with aq HCl (2 N), and extracted with
EtOAc three times. The combined organic phase was washed with water and brine,
successively, and dried over anhydrous Na2SO4 overnight. After removal of solvent in
vacuo, the crude product was purified by flash column chromatography (gradient elution:
EtOAc/petroleum ether, 0-70%) to give the corresponding target compound.
5.1.7.1. N-methyl-4-chloro-2-(N-(4-methoxy)phenyl-N-methylamino)benzamide (3d):
Starting with 3a (115 mg, 0.38 mmol) at 120 °C for 2 h to produce 92 mg of 3d, 79% yield,
yellow oil; 1H NMR δ ppm 2.89 (3H, d, J = 5.2 Hz, NCH3), 3.12 (3H, s, NCH3), 3.78 (3H, s,
OCH3), 6.82 (4H, m, ArH on the B-ring), 7.02 (1H, d, J = 2.0 Hz, ArH-3), 7.26 (1H, m,
ArH-5), 8.14 (1H, d, J = 8.0, ArH-6). MS m/z (%) 305 (M + 1, 12) 307 (M + 3, 4), 274 (M −
31, 100).
5.1.7.2. 3-Chloro-5-(N-(4-methoxyphenyl)-N-methylamino)-N-methylbenzamide (4d):
Starting with 4a (61 mg, 0.20 mmol) at 100 °C for 1 h to produce 52 mg of 4d, 85% yield,
white solid, mp 144~145 °C; 1H NMR δ ppm 2.96 (3H, d, J = 4.8 Hz, NCH3), 3.26 (3H, s,
NCH3), 3.83 (3H, s, OCH3), 5.96 (1H, s, CONH), 6.73 (1H, s, ArH-2), 6.93 (2H, d, J = 8.8
Hz, ArH-2′,6′), 6.96 (1H, s, ArH-4), 6.99 (1H, s, ArH-6), 7.10 (2H, d, J = 8.8 Hz, ArH-3′,
5′). MS m/z (%) 305 (M + 1, 100), 307 (M + 3, 31); HPLC purity 99.3%.
5.1.7.3. 5-(N-(4-Methoxyphenyl)-N-methylamino)-3-trifluoromethyl-N-
methylbenzamide (4e): Starting with 4b (102 mg, 0.30 mmol) at 100 °C for 1 h to produce
90 mg of 4e in 89% yield, yellow solid, mp 115~116 °C; 1H NMR δ ppm 2.99 (3H, d, J =
4.8 Hz, NCH3), 3.31 (3H, s, NCH3), 3.84 (3H, s, OCH3), 6.05 (1H, s, CONH), 6.94 (2H, d, J
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= 8.8 Hz, ArH-2',6'), 6.97 (1H, s, ArH-2), 7.11 (2H, d, J = 8.8 Hz, ArH-3',5′), 7.20 (1H, s,
ArH-4), 7.26 (1H, s, ArH-6). MS m/z (%) 339 (M + 1, 100); HPLC purity 96.3%.
5.1.7.4. 3-Bromo-5-(N-(4-methoxyphenyl)-N-methylamino)-N-methylbenzamide (4f):
Starting with 4c (100 mg, 0.29 mmol) at 100 °C for 1 h to produce 82 mg of 4f in 82% yield,
white solid, mp 155~156 °C; 1H NMR δ ppm 2.96 (3H, d, J = 4.4 Hz, NCH3), 3.26 (3H, s,
NCH3), 3.83 (3H, s, OCH3), 5.98 (1H, s, CONH), 6.89 (1H, s, ArH-2), 6.93 (2H, d, J = 8.8
Hz, ArH-2′,6′), 7.03 (1H, s, ArH-4), 7.08 (1H, s, ArH-6), 7.10 (2H, d, J = 8.8 Hz, ArH-3′,
5′). MS m/z (%) 349 (M + 1, 100), 351 (M + 3, 95); HPLC purity 97.9%.
5.1.8. 3-Bromo-5-(N-(4-methoxyphenyl)-N-methylamino)-N,N-
dimethylbenzamide (4g)—Prepared in the same manner as 3c. Starting with 4f (70 mg,
0.20 mmol), methyl iodide (0.02 mL, 0.32 mmol) and NaH (16 mg, 0.40 mmol) to produce
65 mg of 4g, 90% yield, brown solid, mp 80~81 °C; 1H NMR δ ppm 2.94 (3H, s, NCH3),
3.05 (3H, s, NCH3), 3.23 (3H, s, NCH3), 3.83 (3H, s, OCH3), 6.61 (1H, dd, J = 1.2 Hz and
1.2 Hz, ArH-4) 6.82 (1H, m, ArH-2), 6.83 (1H, m, ArH-6), 6.92 (2H, d, J = 8.8 Hz, ArH-2′,
6′), 7.10 (2H, d, J = 8.8 Hz, ArH-3′,5′). MS m/z (%) 363 (M + 1, 100), 365 (M + 3, 95);
HPLC purity 98.4%.
5.1.9. 3-Bromo-5-(N-(4-methoxyphenyl)-N-methylamino)benzoic acid (4h)—To a
solution of 4c (76 mg, 0.20 mmol) in THF/MeOH (2/2 mL) was added aq NaOH (3 N, 2
mL), and the mixture was heated at reflux for 5 h. After removal of solvent in vacuo, the
mixture was poured into ice-water, and the insoluble solid (pH 12) was removed by
filtration. The filtrate was acidified to pH 2, until there was no further precipitation. The
solid was collected by filtration, washed with water until neutral, and dried to obtain 178 mg
of 4h in 90% yield, yellow solid, mp 242~244 °C; 1H NMR (DMSO-d6) δ ppm 3.17 (3H, s,
NCH3), 3.77 (3H, s, OCH3), 7.46 (1H, m, ArH-4), 6.97 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.11
(2H, d, J = 8.8 Hz, ArH-3′,5′), 7.18 (1H, d, J = 1.2 Hz, ArH-6), 7.31 (1H, s, ArH-2). MS m/z
(%) 336 (M + 1, 100), 338 (M + 3, 97).
5.1.10. 3-Bromo-5-(N-(4-methoxyphenyl)-N-methylamino)-N-
cyclopropylbenzamide (4i)—A mixture of 4h (105 mg, 0.31 mmol), EDCI (90 mg, 0.47
mmol), and HOBt (64 mg, 0.47 mmol) in CH2Cl2 (5 mL) was stirred at rt for 30 min, and
then cyclopropylamine (27 mg, 0.47 mmol) was added dropwise at 0 °C with stirring over
15 min, followed by warming to rt for an additional 24 h. The mixture was added to water
(20 mL) and extracted with CH2Cl2 three times. The combined organic phase was washed
with water and brine, successively, and dried over anhydrous Na2SO4 overnight. After
removal of solvent in vacuo, crude product was purified by flash column chromatography
(gradient elution: EtOAc/petroleum ether, 0-50%) to give 95 mg of pure 4i in 82% yield,
white solid, mp 184-186 °C; 1H NMR δ ppm 0.59 (2H, m, CH2), 0.85 (2H, m, CH2), 2.84
(1H, m, CH), 3.26 (3H, s, NCH3), 3.83 (3H, s, OCH3), 6.09 (1H, br, NH), 6.87 (1H, dd, J =
1.6 & 2.0 Hz, ArH-2), 6.93 (2H, d, J = 8.8 Hz, ArH-2′,6′), 7.05 (2H, m, ArH-4,6), 7.09 (2H,
d, J = 8.8 Hz, ArH-3′,5′). MS m/z (%) 375 (M + 1, 69), 377 (M + 3, 79), 320 (M - 54, 100);
HPLC purity 99.1%.
5.1.11. 3-Bromo-5-(N-(4-methoxyphenyl)-N-methylamino)-N-
cyclopentylbenzamide (4j)—As for 4i. Starting with 4h (168 mg, 0.50 mmol), EDCI
(144 mg, 0.75 mmol), HOBt (101 mg, 0.75 mmol), and cyclopentylamine (64 mg, 0.75
mmol) to produce 161 mg of 4j in 80% yield, white solid, mp 173-174 °C; 1H NMR δ
ppm1.46 (2H, m, CH2), 1.69 (4H, m, 2×CH2), 2.08 (2H, m, CH2), 3.26 (3H, s, NCH3), 3.83
(3H, s, OCH3), 4.33(1H, m, CH), 5.90 (1H, br, NH), 6.86 (1H, dd, J = 2.0 and 2.0 Hz,
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ArH-2), 6.93 (2H, d, J = 10.0 Hz, ArH-2′,6′), 7.04 (1H, s, ArH-4), 7.10 (3H, m, ArH-3′,5′,
6). MS m/z (%) 403 (M + 1, 100), 405 (M + 3, 91).
5.1.12. N-(3-Chloro-5-carbomethoxy)phenyl-6-methoxy-1,2,3,4-
tetrahydroquinoline (5a)—Prepared in the same manner as 2b. Starting with methyl 3-
chloro-5-iodobenzoate (297 mg, 1.0 mmol), 6-methoxy-1,2,3,4-tetrahydroquinoline (7) (163
mg, 1.0 mmol) at 120 °C for 30 min to produce 255 mg of 5a in 77% yield, yellow oil; 1H
NMR δ ppm 1.96 (2H, m, 3′-CH2), 2.76 (2H, t, J = 6.4 Hz, 4′-CH2), 3.61 (2H, t, J = 6.4 Hz,
2′-CH2), 3.78 (3H, s, OCH3), 3.89 (3H, s, OCH3), 6.64 (1H, d, J = 3.2 Hz, ArH-5′), 6.67
(1H, dd, J = 8.8 & 3.2 Hz, ArH-7′), 6.96 (1H, d, J = 8.8 Hz, ArH-8′), 7.28 (1H, m, ArH-6),
7.51 (1H, m, ArH-4), 7.66 (1H, m, ArH-2). MS m/z (%) 332 (M + 1, 100), 334 (M + 3, 30);
HPLC purity 97.2%.
5.1.13. N-(3-Bromo-5-carbomethoxy)phenyl-6-methoxy-1,2,3,4-
tetrahydroquinoline (5b)—Prepared in the same manner as 2d. Starting with methyl 3,5-
dibromobenzoate (294 mg, 1.0 mmol), 7 (179 mg, 1.1 mmol) for 12 h to produce 255 mg of
5b in 68% yield, yellow oil; 1H NMR δ ppm 1.96 (2H, m, 3′-CH2), 2.76 (2H, t, J = 6.4 Hz,
4′-CH2), 3.61 (2H, t, J = 6.4 Hz, 2′-CH2), 3.78 (3H, s, OCH3), 3.89 (3H, s, OCH3), 6.65
(1H, dd, J = 9.2 and 2.8 Hz, ArH-7′), 6.68 (1H, d, J = 2.8 Hz, ArH-5′), 6.95 (1H, d, J = 9.2
Hz, ArH-8′), 7.43 (1H, t, J = 2.0 Hz, ArH-4), 7.66 (1H, t, J = 2.0 Hz, ArH-6), 7.66 (1H, m,
ArH-2). MS m/z (%) 376 (M + 1, 100), 378 (M + 3, 91).
5.1.14. N-(3-Chloro-5-(N-methyl) carbamoyl)phenyl-6-methoxy-1,2,3,4-
tetrahydroquinoline (5c)—Prepared in the same manner as 3d. Starting with 5a (100
mg, 0.30 mmol) at 100 °C for 1 h to produce 91 mg of 5c, 92% yield, pale yellow solid, mp
179~180 °C; 1H NMR δ ppm 1.96 (2H, m, 3′-CH2), 2.75 (2H, t, J = 6.0 Hz, 4′-CH2), 2.98
(3H, d, J = 4.8 Hz, NCH3), 3.61 (2H, t, J = 6.0 Hz, 2′-CH2), 3.78 (3H, s, OCH3), 6.05 (1H,
bs, NH), 6.68 (2H, m, ArH-5′,7′), 6.97 (1H, d, J = 8.4 Hz, ArH-8′), 7.17 (1H, d, J = 1.6 Hz,
ArH-6), 7.20 (1H, d, J = 1.6 Hz, ArH-4), 7.40 (1H, s, ArH-2). MS m/z (%) 331 (M + 1,
100), 333 (M + 3, 32); HPLC purity 99.0%.
5.1.15. N-(3-Bromo-5-(N-methyl)carbamoyl)phenyl-6-methoxy-1,2,3,4-
tetrahydroquinoline (5d)—Prepared in the same manner as 3d. Starting with 5b (64 mg,
0.17 mmol) at 100 °C for 1 h to produce 57 mg of 5d, 92% yield, white solid, mp
161~162 °C; 1H NMR δ ppm 1.96 (2H, m, 3′-CH2), 2.75 (2H, t, J = 6.0 Hz, 4′-CH2), 2.99
(3H, d, J = 4.8 Hz, NCH3), 3.60 (2H, t, J = 6.0 Hz, 2′-CH2), 3.78 (3H, s, OCH3), 6.02 (1H,
bs, NH), 6.68 (2H, m, ArH-5′,7′), 6.96 (1H, d, J = 8.4 Hz, ArH-8′), 7.32 (1H, s, ArH-4), 7.36
(1H, s, ArH-6), 7.44 (1H, s, ArH-2). MS m/z (%) 375 (M + 1, 100), 377 (M + 3, 97); HPLC
purity 98.2%.
5.1.16. N-(3-Bromo-5-carboxy)phenyl-6-methoxy-1,2,3,4-tetrahydroquinoline
5e—Prepared in the same manner as (4h). Starting with 5b (226 mg, 0.60 mmol) to produce
178 mg of 5e in 82% yield, yellow solid, mp 176~178 °C; 1H NMR δ ppm 1.97 (2H, m, 3′-
CH2), 2.76 (2H, t, J = 6.0 Hz, 4′-CH2), 3.61 (2H, t, J = 6.0 Hz, 2′-CH2), 3.79 (3H, s, OCH3),
6.68 (2H, m, ArH-5′,7′), 6.98 (2H, d, J = 8.8 Hz, ArH-8′), 7.48 (1H, t, J = 2.0 Hz, ArH-6),
7.70 (1H, dd, J = 2.0 and 1.6 Hz, ArH-4), 7.48 (1H, dd, J = 2.0 and 1.6 Hz, ArH-2). MS m/z
(%) 362 (M + 1, 100), 364 (M + 3, 72).
5.1.17. N-(3-Bromo-5-(N-cyclopropyl)carbamoyl)phenyl-6-methoxy-1,2,3,4-
tetrahydroquinoline 5f—Prepared in the same manner as 4i. Starting with 5e (109 mg,
0.30 mmol), EDCI (115 mg, 0.60 mmol), HOBt (81 mg, 0.60 mmol), and cyclopropylamine
(56 mg, 1.0 mmol) to produce 108 mg of 5f in 90% yield, white solid, mp 163-164 °C; 1H
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NMR δ ppm 0.61 (2H, m, CH2), 0.86 (2H, m, CH2), 1.95 (2H, m, 3′-CH2), 2.75 (2H, t, J =
6.4 Hz, 4′-CH2), 2.86 (1H, m, CH), 3.60 (2H, t, J = 6.0 Hz, 2′-CH2), 3.78 (3H, s, OCH3),
6.12 (1H, br, NH), 6.66 (2H, m, ArH-5′,7′), 6.95 (1H, d, J = 8.4 Hz, ArH-8′), 7.26 (1H, t, J =
2.0 Hz, ArH-4), 7.35 (1H, d, J = 2.0 Hz, ArH-2), 7.43 (1H, t, J = 2.0 Hz, ArH-6); 13C NMR
δ ppm 6.91 (CH2), 23.38 (CH), 23.39 (CH2), 27.71 (CH2), 49.78 (CH2), 55.71 (OCH3),
112.59 (CH), 114.35 (CH), 117.61 (CH), 120.62 (CH), 121.48 (CH), 123.02 (C), 125.54
(CH), 130 40 (C), 135.66 (C), 137.15 (C), 150.75 (C), 154.51 (C), 167.95 (C), 195.50 (CO).
MS m/z (%) 401 (M + 1, 100), 403 (M + 3, 90); HPLC purity 98.4%.
5.1.18. 6-Methoxy-N-(naphthalen-1-yl)-1,2,3,4-tetrahydroquinoline 6a—Prepared
in the same manner as (2d). Starting with 1-bromonaphthalene (206 mg, 1.0 mmol) and 7
(179 mg, 1.1 mmol) for 12 h to produce 196 mg of 6a in 68% yield, pale yellow solid, mp
93-95 °C; 1H NMR δ ppm 2.15 (2H, br, 3-CH2), 2.98 (2H, br, 4-CH2), 3.63 (2H, t, J = 5.6
Hz, 2-CH2), 3.72 (3H, s, 6-OCH3), 6.06 (1H, d, J = 8.8 Hz, ArH-8), 6.41 (1H, dd, J = 8.8 &
2.8 Hz, ArH-7), 6.68 (1H, d, J = 2.8 Hz, ArH-5), 6.97 (1H, d, J = 7.2 Hz, ArH-2′), 7.46 (3H,
m, ArH-3′,6′,7′), 7.74 (1H, d, J = 8.0 Hz, ArH-4′), 7.89 (1H, d, J = 8.0 Hz, ArH-5′), 8.02
(1H, d, J = 8.0 Hz, ArH-8′). MS m/z (%) 290 (M + 1, 100), 274 (M-15, 100); HPLC purity
98.2%.
5.1.19. 6-Methoxy-2′-methyl-3,4-dihydro-2H-1,4′-biquinoline 6b—Prepared in the
same manner as (2d). Starting with 4-chloro-2-methylquinoline (178 mg, 1.0 mmol) and 7
(180 mg, 1.1 mmol) for 12 h to produce 228 mg of 6b in75% yield, yellow solid, mp
120~121 °C; 1H NMR δ ppm 2.03 (2H, m, 3-CH2), 2.65 (3H, s, 2′-CH3), 2.94 (2H, t, J = 6.4
Hz, 4-CH2), 3.71 (2H, t, J = 5.6 Hz, 2-CH2), 3.77 (3H, s, 6-OCH3), 6.46 (1H, d, J = 9.2 Hz,
ArH-8), 6.53 (1H, dd, J = 9.2 & 2.8 Hz, ArH-7), 6.71 (1H, d, J = 2.8 Hz, ArH-5), 6.97 (1H,
s, ArH-3′), 7.38 (1H, m, ArH-6′), 7.64 (1H, m, ArH-7′), 7.90 (1H, d, J = 8.4 Hz, ArH-8′),
8.01 (1H, d, J = 8.4 Hz, ArH-5′) ); 13C NMR δ ppm 22.41 (CH2), 25.59 (CH3), 27.67 (CH2),
51.39 (CH2), 55.68 (OCH3), 112.78 (CH), 114.34 (CH), 116.44 (CH), 120.25 (CH), 123.58
(C), 124.31 (CH), 124.96 (CH), 127.55 (C), 129.27 (CH), 129.50 (CH), 138.14 (C), 149.92
(C), 153.93 (C), 154.75 (C), 159.78 (C). MS m/z (%) 305 (M + 1, 100); HPLC purity
99.3%.
5.1.20. 6-Methoxy-N-(2′-methylquinazol-4′-yl)-1,2,3,4-tetrahydroquinoline (6c)
—A mixture of 4-chloro-2-methylquinazoline (89 mg, 0.5 mmol), 7 (98 mg, 0.5 mmol), and
NaHCO3 (126 mg, 1.5 mmol) in absolute anhydrous EtOH (5 mL) was refluxed for 3 h. The
mixture was poured into ice-water, acidified to pH 3 with aq HCl (2 N), and extracted with
EtOAc three times. The combined organic phases were washed with water and brine,
successively, and dried over anhydrous Na2SO4 overnight. After removal of solvent in
vacuo, the crude product was purified by flash column chromatography (gradient elution:
EtOAc/petroleum ether, 0-50%) to obtain 121 mg of pure 6c in79% yield, yellow solid, mp
134~136 °C; 1H NMR δ ppm 2.11 (2H, m, 3′-CH2), 2.73 (3H, s, CH3), 2.88 (2H, t, J = 6.8
Hz, 4′-CH2), 3.79 (3H, s, OCH3), 4.05 (2H, t, J = 6.8 Hz, 2′-CH2), 6.53 (1H, dd, J = 8.8 &
2.8 Hz, ArH-7′), 6.63 (1H, d, J = 8.8 Hz, ArH-8′), 6.78 (1H, d, J = 2.8 Hz, ArH-5′), 7.12
(1H, m, ArH-6), 7.32 (1H, dd, J = 8.4 &1.2 Hz, ArH-5), 7.62 (1H, m, ArH-7), 7.79 (1H, d, J
= 8.0 Hz, ArH-8) ; 13C NMR δ ppm 24.42 (CH2), 26.65 (CH3), 27.39 (CH2), 47.49 (CH2),
55.62 (OCH3), 112.00 (CH), 113.70 (CH), 115.68 (C), 122.28 (CH), 124.40 (CH), 126.29
(CH), 128.00 (CH), 132.35 (CH), 132.45 (C), 136.22 (C), 152.43 (C), 156.07 (C), 161.95
(C), 163.99 (C). MS m/z (%) 306 (M + 1, 100); HPLC purity 98.8%.
5.1.21. N-(2′-Chloroquinazol-4′-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline (6d)
—Similar procedure to that of 6c. Starting with 2,4-dichloroquinazoline (200 mg, 1.0
mmol), 7 (163 mg, 1.0 mmol), and NaHCO3 (252 mg, 3.0 mmol) in absolute anhydrous
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EtOH (8 mL) for 3 h to produce 282 mg of 6d in 87% yield, yellow solid, mp
136~138 °C; 1H NMR δ ppm 2.12 (2H, m, 3′-CH2), 2.86 (2H, t, J = 6.8 Hz, 4′-CH2), 3.81
(3H, s, OCH3), 4.07 (2H, t, J = 6.8 Hz, 2′-CH2), 6.55 (1H, dd, J = 8.8 &2.8 Hz, ArH-7′),
6.70 (1H, d, J = 8.8 Hz, ArH-8′), 6.81 (1H, d, J = 2.8 Hz, ArH-5′), 7.13 (1H, m, ArH-6),
7.32 (1H, dd, J = 8.8 &1.2 Hz, ArH-5), 7.63 (1H, m, ArH-7), 7.78 (1H, dd, J = 8.8 Hz and
1.2 Hz, ArH-8) ; 13C NMR δ ppm 23.67 (CH2), 26.84 (CH2), 48.86 (CH2), 55.78 (OCH3),
112.82 (CH), 113.14 (C), 114.06 (CH), 123.21 (CH), 123.99 (CH), 126.68 (CH×2), 132.44
(C), 135.44 (CH), 135.86 (C), 145.79 (C), 152.50 (C), 159.10 (C), 160.89 (C). MS m/z (%)
326 (M + 1, 100), 328 (M + 3, 31); HPLC purity 98.4%.
5.1.22. 6-Methoxy-N-(2′-(N-methyl)aminoquinazol-4′-yl)-1,2,3,4-
tetrahydroquinoline (6e)—Prepared in the same manner as 3d. Staring with 6d (65 mg,
0.20 mmol) in 3 mL of methylamine (30%) was heated to 100 ºC for 1 h to produce 42 mg
of 6e in 66% yield, yellow solid, mp 139~140 °C; 1H NMR δ ppm 2.07 (2H, m, 3′-CH2),
2.85 (2H, t, J = 6.8 Hz, 4′-CH2), 3.10 (3H, d, J = 5.2 Hz, NCH3), 3.79 (3H, s, OCH3), 3.94
(2H, t, J = 6.8 Hz, 2′-CH2), 6.53 (1H, dd, J = 9.2 & 2.8 Hz, ArH-7′), 6.67 (1H, d, J = 9.2 Hz,
ArH-8′), 6.76 (1H, d, J = 2.8 Hz, ArH-5′), 6.83 (1H, m, ArH-6), 7.29 (1H, d, J = 8.0 Hz,
ArH-5), 7.46 (1H, m, ArH-7), 7.52 (1H, d, J = 8.0 Hz, ArH-8). MS m/z (%) 321 (M + 1,
100); HPLC purity 98.6%.
5.2. Antiproliferative Activity Assay
Target compounds were assayed by the SRB method for cytotoxic activity using a HTCL
assay according to procedures described previously [22-24]. The panel of cell lines included
human lung carcinoma (A-549), epidermoid carcinoma of the nasopharynx (KB), P-gp-
expressing epidermoid carcinoma of the nasopharynx (KBvin), and prostate cancer
(DU145). The cytotoxic effects of each compound were expressed as GI50 values, which
represent the molar drug concentrations required to cause 50% tumor cell growth inhibition.
5.3. Tubulin Assays
Tubulin assembly was measured by turbidimetry at 350 nm as described previously [25].
Assay mixtures contained 1.0 mg/mL (10 μM) tubulin and varying compound
concentrations were pre-incubated for 15 min at 30 °C without guanosine 5′-triphosphate
(GTP). The samples were placed on ice, and 0.4 mM GTP was added. Reaction mixtures
were transferred to 0 °C cuvettes, and turbidity development was followed for 20 min at 30
°C following a rapid temperature jump. Compound concentrations that inhibited increase in
turbidity by 50% relative to a control sample were determined.
Inhibition of the binding of [3H]colchicine to tubulin was measured as described previously
[26]. Incubation of 1.0 μM tubulin with 5.0 μM [3H]colchicine and 5.0 μM or 1.0 μM
inhibitor was for 10 min at 37 °C, when about 40-60% of maximum colchicine binding
occurs in control samples.
5.4. Aqueous Solubility
Determination—Solubility was measured at pH 7.4 by using an HPLC−UV method. Test
compounds were initially dissolved in DMSO at a concentration of 1.0 mg/mL. Ten
microliters of this stock solution were added to pH 7.4 phosphate buffer (1.0 mL) with the
final DMSO concentration being 1%. The mixture was stirred for 4 h at rt and then
centrifuged at 3000 rpm for 10 min. The saturated supernatants were transferred to other
vials for analysis by HPLC−UV. Each sample was performed in triplicate. For
quantification, a model 1200 HPLC−UV (Agilent) system was used with an Agilent Eclipse
XDB-C18 column (150 mm × 4.6 mm, 5 μm) and elution was with 50%-80% ACN in water.
The flow rate was 0.8 mL/min, and injection volume was 20 μL. Aqueous concentration was
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determined by comparison of the peak area of the saturated solution with a standard curve
plotted peak area versus known concentrations, which were prepared by solutions of test
compound in ACN at 50,12.5, 3.13, 0.78, and 0. 20 μg/mL.
5.5. Log P Measurement
One to two mg of test compound was dissolved in 1.0−2.0 mL of n-octane to obtain a 1.0
mg/mL solution. Next, the same volume of water as n-octane was added to each vial. The
mixture was stirred at rt for 24 h, and then was left without stirring overnight. The aqueous
and organic phases of each mixture were transferred to separate vials for HPLC analysis.
The instrument and conditions were the same as those for water solubility determinations.
The log P was calculated by the peak area ratio in n-octane and in water.
5.6. Microsomal Stability Assay
Stock solutions of test compounds (1 mg/mL) were prepared by dissolving the pure
compound in DMSO, and the solutions were stored at 4 °C. Before assay, the stock solution
was diluted with ACN to 0.1 mM. For measurement of metabolic stability, all compounds
were brought to a final concentration of 1 μM with 0.1 M potassium phosphate buffer at pH
7.4, which contained 0.1 mg/mL human liver microsomes and 5 mM MgCl2. The incubation
volumes were 300 μL, and reaction temperature was 37 °C. Reactions were started by
adding 60 μL of NADPH (final concentration, 1.0 mM) and quenched by adding 600 μL of
ice-cold ACN to stop the reaction at 5, 15, 30, and 60 min time points. Samples at the 0 min
time point were prepared by adding 600 μL of ice-cold ACN first, followed by 60 μL of
NADPH. All samples were prepared in duplicate. After quenching, all samples were
centrifuged at 12000 rpm for 5 min at 0 °C. The supernatant was collected, and 20 μL of the
supernatant was directly injected into a Shimadzu LC−MS 2010 system with an electrospray
ionization source for further analysis. The following controls were also used: (1) positive
control incubation containing liver microsomes, NADPH, reference compound propranolol
or terfenadine; (2) negative control incubation omitting NADPH; (3) baseline control
containing only liver microsomes and NADPH. The peak heights of test compounds at
different time points were converted to percentage of compound remaining, and the peak
height values at initial time (0 min) served as 100% values. The slope of the linear
regression from log percentage remaining versus incubation time relationships (−k) was
used to calculate the in vitro half-life (t1/2) by the formula of in vitro t1/2 = 0.693/k, regarded
as first-order kinetics. Conversion to in vitro CLint (in units of mL/min/mg of protein) was
calculated by the formula CLint = [0.693/(in vitro t1/2)][(mL incubation)/(mg of
microsomes)]. The HPLC−MS analysis was carried out on a Shimadzu LC−MS 2010 with
an electrospray ionization source. An Alltima C18 column (5 μm, 150 mm × 2.1 mm) was
used for HPLC with a gradient elution at a flow rate of 0.2 mL/min. The elution condition
was ACN (B) in water (A) at 30% for 0−2 min, 85% for 2−6 min, 100% for 6−9 min and
30% for 9−12 min. The MS conditions were optimized to a detector voltage of +1.7 kV,
with acquisition mode selected ion monitoring of the appropriate molecular weights of the
test compounds. The curved desolvation line temperature was 250 °C, heat block
temperature was 200 °C, and neutralizing gas flow was 1.5 L/min. Samples were injected by
an autosampler. Electrospray ionization was operated in positive and negative modes.
5.7. Molecular Modeling Studies
All molecular modeling studies were performed with Discovery Studio 3.0 (Accelrys, San
Diego, USA). The crystal structures of tubulin in complex with DAMA-colchicine (PDB:
1SA0) and with TN16 (PDB: 3HKD) were downloaded from the RCSB Protein Data Bank
(http://www.rcsb.org/pdb) for possible use in the modeling study. We selected the structure
1SA0 as our modeling system. CDOCKER was used to evaluate and predict in silico
binding free energy of the inhibitors and automated docking. The protein protocol was
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prepared by several operations, including standardization of atom names, insertion of
missing atoms in residues and removal of alternate conformations, insertion of missing loop
regions based on SEQRES data, optimization of short and medium size loop regions with
Looper Algorithm, minimization of remaining loop regions, calculation of pK, and
protonation of the structure. The receptor model was typed with the CHARMm force field.
A binding sphere with radius of 8.5 Å was defined through the original ligand (DAMA-
colchicine) as the binding site for the study. The docking protocol employed total ligand
flexibility, and the final ligand conformations were determined by the simulated annealing
molecular dynamics search method set to a variable number of trial runs. The docked
ligands (4i, 5f, and 6d) were further refined using in situ ligand minimization with the Smart
Minimizer algorithm by standard parameters. The ligand and its surrounding residues within
the above defined sphere were allowed to move freely during the minimization, while the
outer atoms were frozen. The implicit solvent model of Generalized Born with Molecular
Volume (GBMV) was also used to calculate the binding energies.
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Refer to Web version on PubMed Central for supplementary material.
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New N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines inhibited tubulin polymerization.
Compound 6d significantly inhibited colchicine binding (99%, 5 μM; 95%, 1 μM).
Compound 6d was more potent than anticancer drug paclitaxel (GI50 1.5–1.7 nM). A
fused aromatic ring, such as quinoline and quinazoline, improved molecular potency A
feasible torsional angle between the two aryl rings is important for high potency.
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Colchicine, DAMA-colchicine, and clinical trial candidates targeted at the colchicine site of
tubulin.
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Modification strategies and new target compounds 3–6 series
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(A) Predicted modes for 4i (purple stick) and 5f (green) binding with tubulin (PDB code:
1SA0), and overlapping with DAMA-colchicine (cyan, the native ligand of 1SA0); (B)
Superimposition of docked compound 6d (orange) with DAMA-colchicine (cyan).
Surrounding amino acid side chains are shown in gray stick format and labeled. Hydrogen
bonds are shown by green dashed lines, and the distance between ligands and protein is less
than 3 Å.
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a) i. K2CO3, Cu, Cu2O, 2-ethoxyethanol, N2, 130 °C, 24 h, 67%; ii. DMF-DMA in toluene,
reflux, 2 h, 85%; b) i. Cs2CO3, Pd(OAc)2, X-Phos, Celite, toluene/t-BuOH, N2, mw,
120-150 °C, 30-60 min, 74% for 2b and 2c; c) Cs2CO3, Pd(OAc)2, BINAP, toluene, N2,
reflux 12 h, 64% for 2d; d) MeI/NaH (60% oil suspension), 0 °C, 1 h; e) LiAlH4/THF, 0 °C,
1 h, 97%; f) 30% NH2Me/MeOH, 100-120 °C, mw, 1-2 h for 3d, 4d-f; g) MeOH/THF, 3N
NaOH aq, reflux, 5 h, 90% for 4h; h) EDCI, HOBt, cyclopropylamine or cyclopentylamine,
CH2Cl2, rt, 24 h for 4i and 4j.
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a) Cs2CO3, Pd(OAc)2, X-Phos, Celite, N2, mw, 120 °C, 30 min, 77% for 5a; b) Cs2CO3,
Pd(OAc)2, BINAP, toluene, N2, reflux, 12 h, 68-75% for 5b and 6a-6b; c) 30% NH2Me/
MeOH, 100 °C, mw, 1 h for 5c, 5d, and 6e; d) MeOH/THF, 3 N NaOH aq, reflux, 5 h, 82%
for 5e; e) EDCI, HOBt, cyclopropylamine, CH2Cl2, rt, 24 h, 90%; f) NaHCO3/EtOH, reflux,
3 h for 6c and 6d.
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Table 1
Cytotoxicity of series 3–5 compounds against human tumor cell lines (HTCL)
X R1
GI50 (μM)a
A549 KB KBvin DU145
1a 0.23±0.01 0.26±0.04 0.20±0.03 0.21±0.04
3a Cl o-COOMe 3.36±0.49 1.98±0.37 1.89±0.17 1.68±0.04
3b Cl o-CH2OH 21.7±2.53 19.5±1.33 18.1±2.24 16.0±2.73
3c Cl o-CH2OMe 4.53±0.84 5.24±0.42 2.85±0.62 3.13±0.35
3d Cl o-CONHMe 43.2±4.81 188±33.8 61.0±5.13 98.9±4.22
4a Cl m-COOMe 1.60±0.36 1.61±0.08 1.57±0.10 1.46±0.16
4b CF3 m-COOMe 15.1±2.6 13.5±1.21 13.1±1.41 11.5±1.71
4c Br m-COOMe 1.24±0.34 1.36±0.17 1.20±0.39 0.97±0.08
4d Cl m-CONHMe 0.27±0.01 0.30±0.04 0.23±0.04 0.23±0.03
4e CF3 m-CONHMe 14.7±2.23 12.3±1.72 12.6±1.81 11.9±2.20
4f Br m-CONHMe 0.25±0.07 0.21±0.03 0.14±0.01 0.16±0.07
4g Br m-CONMe2 2.83±0.59 6.52±1.16 2.38±0.37 3.34±0.54
4h Br m-COOH NAb NA NA NA
4i Br 0.17±0.02 0.17±0.02 0.17±0.02 0.17±0.02
4j Br 0.12±0.02 0.12±0.01 0.12±0.01 0.11±0.01
5a Cl m-COOMe 2.23±0.23 2.33±0.47 1.78±0.31 1.51±0.46
5b Br m-COOMe 1.12±0.14 1.37±0.31 1.27±0.22 1.28±0.25
5c Cl m-CONHMe 0.74±0.08 1.04±0.11 0.43±0.03 1.02±0.10
5d Br m-CONHMe 0.37±0.08 0.63±0.34 0.93±0.02 0.56±0.09
5f Br 0.17±0.01 0.16±0.03 0.19±0.01 0.15±0.02
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X R1
GI50 (μM)a
A549 KB KBvin DU145
Paclitaxel c 0.0076±0.0017 0.0064±0.0014 1.21±0.19 0.006±0.001
a
Concentration of compound that inhibits 50% human tumor cell growth, presented as mean ± standard deviation (SD), performed at least in
triplicate.
b
Not active; test compound (60 μM) did not reach 50% inhibition.
c
Positive control.
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Table 2
Cytotoxicity of 6 series against human tumor cell lines
Fused A-ring GI50 (μM)a
X Y Z A549 KB KBvin DU145
6a H CH CH 17.8±2.6 15.6±1.3 17.6±2.5 14.8±1.7
6b Me CH N 0.045±0.008 0.091±0.009 0.055±0.010 0.038±0.008
6c Me N N 0.018±0.001 0.011±0.001 0.018±0.004 0.015±0.005
6d Cl N N 0.0017±0.0003 0.0017±0.0008 0.0017±0.0003 0.0015±0.0003
6e NHMe N N 0.027±0.005 0.025±0.002 0.029±0.005 0.023±0.003
Paclitaxel b 0.0076±0.0017 0.0064±0.0014 1.21±0.19 0.006±0.001
a
Concentration of compound that inhibits 50% human tumor cell growth
b
Positive control.
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Table 3
Inhibition of tubulin polymerizationa and colchicine binding to tubulinb
Compound
Inhibition of tubulin assembly
IC50 (μM) ± SD
Inhibition of colchicine binding
(%) inhibition ± SD
at 5 μM at 1 μM
4f 2.2 ± 0.2 71 ± 0.3 NDc
4i 1.6 ± 0.04 69 ± 3.0 ND
5f 1.0 ± 0.1 75 ± 1.0 ND
6b 1.0 ± 0.1 87 ± 2.0 61 ± 2.0
6c 1.0 ± 0.1 98 ± 0.2 89 ± 2.0
6d 0.93 ± 0.04 99 ± 0.6 95 ± 0.7
6e 0.92 ± 0.06 95 ± 0.2 76 ± 0.1
CA4 d 0.96 ± 0.07 98 ± 0.6 90 ± 0.2
a
The tubulin assembly assay measured the extent of assembly of 10 μM tubulin after 20 min at 30 °C.
b
Tubulin: 1 μM. [3H]colchicine: 5 μM. Inhibitor: 5 μM or 1 μM (compounds inhibiting colchicine binding by more than 80% at 5 μM were further




reference compound is a drug candidate in phase II/III clinical trials.
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Table 4







4f 0.81 ± 0.01 4.02 ± 0.11 ND c
4i 0.16 ± 0.03 4.33 ± 0.12 ND
5f 0.26 ± 0.05 4.75 ± 0.09 ND
6b 3.21 ± 0.60 3.98 ± 0.02 7.89
6c 7.67 ± 0.40 3.65 ± 0.03 25.19
6d 0.45 ± 0.06 4.13 ± 0.05 10.59
6e 7.21 ± 0.06 1.07 ± 0.21 25.97
Propranolola 40.82
Terfenadineb 21.14
Data presented as mean from three separate experiments with or without ± standard deviation (SD).
a
Propranolol has moderate metabolic stability with t1/2 of 3–5 h in vivo;
b
Terfenadine has fast metabolic stability with t1/2 of < 3 h in vivo.
c
Not determined.
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